Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 23 Multiple Myeloma 9 Colorectal Neoplasms 9 Carcinoma, Non-Small-Cell Lung 9 Glioma 8 Thyroid Neoplasms 7 Neoplasm Metastasis 7 Hematologic Neoplasms 6 Thyroid Carcinoma, Anaplastic 5 Lymphoma 5 Thyroid Cancer, Papillary 4 Pancreatic Neoplasms 4 Neurofibromatosis 1 4 Neoplasms 4 Lung Neoplasms 3 Brain Neoplasms 3 Astrocytoma 3 Adenocarcinoma, Follicular 3 Skin Neoplasms 2 Recurrence 2 Rectal Neoplasms 2 Prostatic Neoplasms 2 Ovarian Neoplasms 2 Neurofibroma, Plexiform 2 Leukemia, Myelomonocytic, Juvenile 2 Histiocytosis, Langerhans-Cell 2 Glioblastoma 2 Colonic Neoplasms 2 Advanced Solid Tumors 2 Uveal Melanoma 1

Interventions

Doxorubicin 26 pembrolizumab 24 Radiotherapy 20 Cyclophosphamide 18 Magnetic Resonance Spectroscopy 17 Specimen Handling 14 Nivolumab 14 Gemcitabine 13 Ifosfamide 12 Surgical Procedures, Operative 11 Biopsy 11 Radiation 10 X-Rays 8 Temozolomide 8 Ipilimumab 8 pazopanib 7 fludarabine 7 cabozantinib 7 Irinotecan 7 tazemetostat 6 liposomal doxorubicin 6 Trabectedin 6 Surveys and Questionnaires 6 Phantoms, Imaging 6 Blood Specimen Collection 6 olaparib 5 eribulin 5 atezolizumab 5 anlotinib 5 Vincristine 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Sarcoma × trametinib × 1 year × Clear all

NCT03784014 2026-04-29

MULTISARC

Institut National de la Santé Et de la Recherche Médicale, France

Phase 3 Completed

Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡